Haynes W SheppardSummaryAffiliation: California Environmental Protection Agency Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversionHaynes W Sheppard
Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, California 94804, USA
J Acquir Immune Defic Syndr 29:307-13. 2002..The pathogenic potential of these viruses may be different from late-stage X4 virus or early X4 virus acquired by individuals with other CCR5 genotypes...- Inactivated- or killed-virus HIV/AIDS vaccinesHaynes W Sheppard
California Department of Health Services, Richmond, 94804, USA
Curr Drug Targets Infect Disord 5:131-41. 2005.... - Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infectionStephanie A Mulherin
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA
AIDS 17:377-87. 2003..To examine temporal variation in the effects of CCR5-Delta32 and CCR2-64I chemokine receptor gene polymorphisms on HIV-1 disease progression... - Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern AfricaClive M Gray
National Institute for Communicable Diseases, Johannesburg, South Africa
AIDS Res Hum Retroviruses 21:285-91. 2005.... - Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infectionTara M Riddle
UNC Center for AIDS Research, University of North Carolina at Chapel Hill, CB#7295, Chapel Hill, NC 27599-7295, USA
J Virol 80:10591-9. 2006.... - Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1Punnee Pitisuttithum
Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
J Acquir Immune Defic Syndr 37:1160-5. 2004..Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1... - High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversionEleanor Gouws
Medical Research Council, Congella, South Africa
J Acquir Immune Defic Syndr 29:531-5. 2002..The HIV-1 incidence rates provide valuable additional information indicating that new infections are continuing unabated and that the HIV-1 epidemic is still growing in rural South Africa... - Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral loadAgatha Masemola
National Institute for Communicable Diseases, Johannesburg, South Africa
J Virol 78:3233-43. 2004..These data have significance for the design of vaccines and for interpretation of vaccine-induced responses... - Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160Deborah Lee
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Infect Dis 190:903-7. 2004..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection... - Breast milk pasteurization: appropriate assays to detect HIV inactivationCaroline J Chantry
Infect Dis Obstet Gynecol 2006:95938. 2006 - HIV type 1 subtype C gag and nef diversity in Southern AfricaHelba Bredell
Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa
AIDS Res Hum Retroviruses 23:477-81. 2007..We do not, however, find much evidence of intersubtype recombination in the Southern African genes, implying that the likelihood of vaccine failure due to the emergence of intersubtype recombinants is probably low... - Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodiesCecilia Rademeyer
Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Observatory 7925, Cape Town, South Africa
Virology 368:172-81. 2007..Collectively these data provide some insights into design features of an envelope immunogen aimed at inducing neutralizing antibodies... - Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002Carmem A de Freitas Oliveira
Seção de Sorologia, Instituto Adolfo Lutz Secretaria de Estado da Saúde de São Paulo, Av Dr Arnaldo 351, 10 degree andar, 01246 902 São Paulo, Brazil
J Clin Microbiol 43:1439-42. 2005..2 per 100 pregnant women per year (95% confidence interval, 0.041 to 0.608). Western blot profiles suggested an association between results of the STARHS analysis and gp41/gp31 bands... - Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern AfricaAgatha M Masemola
National Institute for Communicable Diseases, University of Witwatersrand, Johannesburg, South Africa
J Immunol 173:4607-17. 2004.... - High incidence and prevalence of HIV-1 infection in high risk population in Calcutta, IndiaPhalguni Gupta
Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania 15261, USA
Int J STD AIDS 14:463-8. 2003..Such a high annual seroincidence rate makes this population well suited for studies of HIV-1 prevention, including vaccine trials... - Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infectionBhupat D Rawal
Blood Centers of the Pacific, San Francisco, California 94118, USA
J Acquir Immune Defic Syndr 33:349-55. 2003..These results support the potential use of the Vironostika-LS EIA for detection of recent HIV-1 infections for incidence projections and for other epidemiologic, clinical, and molecular surveillance applications... - Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infectionStephanie Planque
Chemical Immunology Research Center, Department of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas Houston Medical School, Houston, Texas 77030, USA
AIDS Res Hum Retroviruses 23:1541-54. 2007..The neutralizing activity was specifically inhibited by an electrophilic inhibitor of the catalytic activity. The existence of catalytic IgAs to gp120 in uninfected humans suggests their role in resistance to HIV...
Research Grants
- Whole Inactivated HIV-1; Stabilization and ImmunogenicityHaynes Sheppard; Fiscal Year: 2007..Therefore, this proposal represents a critical step in qualifying this HIV vaccine concept for transition from pre-clinical to clinical studies. ..